Article successfully added.

CyFlow™ CD263 FITC

CyFlow™ CD263 FITC
Alternative Name: DCR1, LIT, TNFRSF10c, TRAILR3 , TRID
Antibody: Yes
Antigen: CD263
Application: Flow cytometry
Clonality: monoclonal
Clone: TRAIL-R3-02
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: FITC
Isotype: IgG1
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CK054023

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 0,1 Quantity 0.1 mg Volume 1.0 mL... more
Close menu
CyFlow™ CD263 FITC
Concentration Unitmg/mL
Concentration0,1
Quantity0.1 mg
Volume1.0 mL
ImmunogenTRAIL-R3 (aa 1-280) - hIgGhc fusion protein
Background InformationCD263 (TRAIL-R3, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumor cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).
UsageThe reagent is designed for Flow Cytometry analysis. Suggested working usage is 3·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor‑4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25; 5(1):54. < PMID: 18518976 > | Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain‑mediated ligand‑independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL‑induced apoptosis. Proc Natl Acad Sci USA. 2005 Dec 13; 102(50):18099‑104. < PMID: 16319225 > | Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL‑mediated DR5‑DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct; 26(19):7046‑55. < PMID: 16980609 > | Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007; 13(4):290‑4. < PMID: 18158563 > | Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling. Int J Biochem Cell Biol. 2007; 39(7‑8):1462‑75. < PMID: 17403612 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet